SIR1-365: meta-analysis of COVID-19 studies

All studies Recovery RCTs All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−88%

RCTs (1)−88%

Late (1)−88%

00.511.5+

← SIR1-365
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

October 2026

SIR1-365 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Qu (DB RCT)−88%1.88 · 0.39–8.90no recov.23 (n)19 (n)

Late treatment−88%1.88 · 0.39–8.9023 (n)19 (n)88% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.44

All studies−88%1.88 · 0.39–8.9023 (n)19 (n)88% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4400.511.52+

Rotate screen for more detailsIncrease width for more details

← SIR1-365
reduces riskSIR1-365
increases risk →

October 2026

SIR1-365 COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Qu (DB RCT)−88%1.88 · 0.39–8.90no recov.23 (n)19 (n)

Late treatment−88%1.88 · 0.39–8.9023 (n)19 (n)88% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.44

All studies−88%1.88 · 0.39–8.9023 (n)19 (n)88% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4400.511.52+

Rotate screen for more detailsIncrease width for more details

← SIR1-365
reduces riskSIR1-365
increases risk →

October 2026

SIR1-365 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Qu (DB RCT)−88%1.88 · 0.39–8.90no recov.23 (n)19 (n)

Late treatment−88%1.88 · 0.39–8.9023 (n)19 (n)88% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.44

All studies−88%1.88 · 0.39–8.9023 (n)19 (n)88% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4400.511.52+

Rotate screen for more detailsIncrease width for more details

← SIR1-365
reduces riskSIR1-365
increases risk →

October 2026

SIR1-365 COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Qu (DB RCT)−88%1.88 · 0.39–8.90no recov.23 (n)19 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← SIR1-365
reduces riskSIR1-365
increases risk →